Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study

Journal of Clinical Oncology

Volumn 12, Issue 8, 1994, Pages 1630-1638

  Muss, Hyman B ^a   Douglas Case, L ^a   Atkins, James N ^a   Bearden III, James D ^a   Cooper, M Robert ^a   Cruz, Julia M ^a   Jackson Jr , Don V ^a   O'Rourke, Mark A ^a   Pavy, Michael D ^a   Powell, Bayard L ^a   Richards II, Frederick ^a   Spurr, Charles L ^a   Eagle, Kaye ^a   White, Douglas R ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0028145106     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.8.1630     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Petru E, Schmahl D: On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klin Wochenschr 65:959-966, 1987
3. Henderson IC: Endocrine therapy of metastatic breast cancer, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1991, pp 559-603
4. Ingle JN: Principles of therapy in advanced breast cancer. Hematol Oncol Clin North Am 3:743-763, 1989
5. Pritchard KI, Sutherland DJA: Diagnosis and therapy of breast cancer: The use of endocrine therapy. Hematol Oncol Clin North Am 3:765-805, 1989
6. Schacter LP, Rozencweig M, Canetta R, et al: Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17:38-46, 1990
7. Muss HB: Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat 21:15-26, 1992
8. Lober J, Rose C, Salimtschik M, et al: Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand 101:39-46, 1981 (suppl)
9. Sedlacek SM, Horwitz KB: The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467-483, 1991
10. Haller DG, Glick JH: Progestational agents in advanced breast cancer: An overview. Semin Oncol 13:2-8, 1986
11. Pannuti F, Martoni A, Piana E, et al: Progestins in breast cancer, in Pannuti F (ed): Hormonotherapy: Results and Perspectives. Pavia, Italy, Edizioni, 1988, pp 207-222
12. Pannuti F, Martoni A, Lenaz GR, et al: A possible new approach to the treatment of metastatic breast cancer: Massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62:499-504, 1978
13. Ganzina F: High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65:563-585, 1979
14. Pannuti F, Martoni A, Di Marco AR, et al: Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593-601, 1979
15. Izuo M, Iino Y, Endo K: Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Breast Cancer Res Treat 1:125-130, 1981
16. Falkson G, Falkson HC: A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer. Cancer Chemother Pharmacol 11:16-18, 1983
17. Guarnieri A, Tucci E, D'Aniello C, et al: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: Clinical results. Chemioterapia 3:320-323, 1984
18. Goss PE, Ashley S, Powles TJ, et al: High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. Cancer Treat Rep 70:777-779, 1986
19. Beex L, Burghouts J, van Turnhout J, et al: Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Cancer Treat Rep 71:1151-1156, 1987
20. Pannuti F, Longhi A, Martoni A, et al: Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Chemioterapia 6:396-398, 1987
21. Davila E, Vogel CL, East D, et al: Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer 61:2161-2167, 1988
22. Della Cuna GR, Calciati A, Strada MRB, et al: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143-149, 1978
23. Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414-419, 1984
24. Gallagher CJ, Cairnduff F, Smith IE: High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895-1900, 1987
25. Mattsson W: A phase III trial of treatment with tamoxifen versus treatment with high dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer, in Iacobelli S, Di Marco A (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors. New York, NY, Raven, 1980, pp 65-71
26. Pannuti F, Martoni A, Fruet F, et al: Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer, in Iacobelli S (ed): The Role of Tamoxifen in Breast Cancer. New York, NY, Raven, 1982, pp 85-92
27. van Veelen H, Willemse PH, Tjabbes T, et al: Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986
28. Hayward JL, Carbone PP, Heuson JG, et al: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289-1293, 1977
29. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
30. Lorenz I, Mechl Z: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer. Neoplasma 32:119-124, 1985
31. Pannuti F, Martoni A, Murari G, et al: Analgesic activity of medroxyprogesterone acetate (MAP) in cancer patients: An antiinflammatory mediated activity? Int J Tissue React 7:505-508, 1985
32. Martoni A, Longhi A, Canova N, et al: High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 48:1-6, 1991